PainReform completed the investment in LayerBio.

PainReform, a biopharmaceutical company that focuses on developing non-opioid pain treatments for patients, completed the investment in LayerBio, a provider of drug delivery solutions. Financial terms were not disclosed. “This transaction has the potential to position PainReform at the forefront of non-opiate innovation in one of the most common and impactful surgical procedures worldwide. LayerBio’s OcuRing™-K is not just a product candidate—it represents a platform technology with the potential to disrupt the way we manage ocular pain and inflammation after surgery. By addressing the ‘dropless’ wishes of the ophthalmic market, we can improve patient outcomes and simplify treatment for providers. We see tremendous promise not only in cataract surgery, but in expanding this technology across additional ophthalmic and surgical indications,” Ehud Geller, PainReform Executive Chairman and Interim CEO.